CHOICE for Veterans Act of 2025

The CHOICE for Veterans Act of 2025, HR3132, was reported out of the House Committee on Veterans' Affairs on May 6, 2025, and is now awaiting floor action. The bill was introduced on May 1, 2025, and referred to the committee, where it underwent consideration and mark-up before being ordered to be reported. This indicates active legislative momentum for the bill. The core mechanism of HR3132, as detailed in Section 3, is to amend title 38, United States Code, to permit fee agreements for services rendered in the preparation, presentation, and prosecution of initial and supplemental claims for benefits under laws administered by the Secretary of Veterans Affairs. This legislative change does not authorize new direct funding but rather modifies the regulatory framework for how veterans can seek assistance with their claims and how those assistance providers are compensated. By allowing fee agreements, the bill aims to incentivize more robust and professional claims assistance, which in turn should lead to more accurate and timely claim submissions to the VA. The structural winners are healthcare providers that serve veterans, as improved claim submissions directly translate to more efficient and potentially higher reimbursement rates from the VA. This positively impacts their revenue cycle management. Companies such as HCA Healthcare ($HCA), Universal Health Services ($UHS), Labcorp Holdings ($LH), and Quest Diagnostics ($DGX) are direct beneficiaries due to their significant operations in hospital services, behavioral health, and diagnostic testing, all of which are utilized by veterans. The bill's sponsor, Rep. Jack Bergman (R-MI-1), a Republican from Michigan, along with 51 cosponsors, indicates broad support for this measure. Recent market data shows a general downward trend for these healthcare providers. As of April 28, 2026, HCA Healthcare ($HCA) is at $430.45, down 8.68% over 7 days and 8.77% over 30 days. Universal Health Services ($UHS) is at $163.81, down 9.36% over 7 days and 10.99% over 30 days. Labcorp Holdings ($LH) is at $259.76, down 4.72% over 7 days and 1.68% over 30 days. Quest Diagnostics ($DGX) is at $195.05, down 4.39% over 7 days and 0.24% over 30 days. Despite these recent declines, the passage of HR3132 would provide a structural tailwind by improving the efficiency of VA reimbursements, which could mitigate future downward pressure or support recovery. Regarding the legislative timeline, the bill has cleared committee and is awaiting a vote on the House floor. If passed by the House, it would then proceed to the Senate for consideration. There are no direct presidential actions that conflict with or amplify this specific bill, as the 'Accelerating Medical Treatments for Serious Mental Illness' Executive Order focuses on psychedelic-based therapies, which is a distinct area from VA claims processing.